Atrial Fibrillation in Diabetes: Epidemiology, Mechanisms and Integrated Management

Area of Science:

• Cardiology
• Endocrinology
• Metabolic Disease

Background:

• Atrial fibrillation (AF) and diabetes mellitus frequently coexist, forming a high-risk cardiometabolic phenotype.
• Diabetes increases AF incidence, influenced by obesity, hypertension, CKD, HF, and metabolic syndrome.
• In established AF, diabetes worsens thromboembolic risk, HF, quality of life, and mortality.

Purpose of the Study:

• To review the epidemiology, mechanisms, and management of AF in the context of diabetes.
• To explore the concept of diabetic atrial cardiomyopathy and its contribution to AF.
• To outline management strategies for AF across the continuum of risk and disease in diabetic patients.

Main Methods:

• Narrative review integrating epidemiological data, mechanistic insights, and clinical management strategies.
• Examination of the "diabetic atrial cardiomyopathy" framework.
• Synthesis of current evidence on AF management in diabetic populations.

Main Results:

• Diabetes contributes to AF through mechanisms including hyperglycemia, insulin resistance, inflammation, and microvascular dysfunction, leading to atrial fibrosis and electrical/mechanical abnormalities.
• Diabetic atrial cardiomyopathy underlies AF initiation, persistence, progression, and recurrence.
• Effective management necessitates cardiometabolic optimization, lifestyle interventions, and tailored AF treatments.

Conclusions:

• AF in diabetes is a complex condition driven by multiple cardiometabolic factors.
• Management must address underlying metabolic derangements alongside AF-specific therapies.
• A holistic approach, including risk factor modification and personalized AF treatment, is crucial for improving outcomes.